In a reproductive‑age woman with endometriosis, can Vitex agnus‑castus be used as a treatment and what is the appropriate dosing?

Vitex agnus-castus for Endometriosis

Vitex agnus-castus should NOT be used as a treatment for endometriosis, as it is not included in evidence-based guidelines and lacks any clinical trial data demonstrating efficacy for endometriosis-specific outcomes.

Guideline-Based Recommendations

ACOG explicitly states that first-line management of endometriosis-related pain must be based on proven medical therapies—progestins, danazol, oral contraceptives, NSAIDs, and GnRH agonists—which have demonstrated reduction in lesion size. 1 Dietary supplements, including Vitex, are not included in ACOG guidelines as standard primary treatments for endometriosis and should not replace established medical therapy. 1

Evidence Gap for Endometriosis

The available research on Vitex agnus-castus addresses entirely different conditions:

• Premenstrual syndrome (PMS): Multiple trials demonstrate efficacy at 20 mg daily for 3 cycles, with significant symptom reduction 2, 3, 4
• Cyclic mastalgia: Meta-analysis shows moderate effect size (SMD: 0.67) for breast pain relief 5
• Menstrual cycle disorders: Real-world data show improvement in dysmenorrhea and irregular cycles 6

None of these studies evaluated endometriosis lesions, endometriosis-related pain, disease progression, or fertility outcomes in confirmed endometriosis patients. The pathophysiology of endometriosis (ectopic endometrial tissue with inflammatory response) differs fundamentally from PMS or mastalgia.

Clinical Algorithm for Endometriosis Management

For a reproductive-age woman with confirmed endometriosis:

1. Initiate proven hormonal therapy: Combined oral contraceptives, progestins (norethindrone acetate, dienogest), or GnRH agonists based on symptom severity and fertility goals 1

2. Add NSAIDs for pain management as needed 1

3. Monitor response over 3-6 months with validated pain scales and quality of life assessments 1

4. Consider surgical intervention if medical therapy fails or fertility is desired 1

Critical Caveats

• No evidence exists that Vitex affects endometriosis lesion size, disease progression, or future fertility 1
• Pregnancy warning: FDA labeling requires consultation with a healthcare professional before use if pregnant or breastfeeding 7
• Discontinuation rule: Stop use if symptoms persist beyond 3 days or worsen 7
• Typical Vitex dosing (when used for approved indications like PMS) is 20 mg daily of standardized extract 2, 3, but this dosing has never been validated for endometriosis

Bottom Line

Continue evidence-based hormonal or surgical therapy as primary treatment for endometriosis. 1 Vitex may address coexisting PMS symptoms but will not treat the underlying endometriosis pathology. Any adjunctive supplement use requires close monitoring of clinical response and should never delay or replace guideline-concordant therapy. 1